Targeting MALT1 proteolytic activity in immunity, inflammation and disease: Good or bad?

Trends in Molecular Medicine

Volumn 22, Issue 2, 2016, Pages 135-150

  Demeyer, Annelies ^a,b   Staal, Jens ^a,b   Beyaert, Rudi ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Inflammation; Lymphocytes; Lymphoma; MALT1; Protease; Therapeutic targeting

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION PROTEIN 1; PEPTIDES AND PROTEINS; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CASPASE; CASPASE INHIBITOR; MALT1 PROTEIN, HUMAN; MALT1 PROTEIN, MOUSE; TUMOR PROTEIN;

ANTIBODY RESPONSE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GENE MUTATION; HUMAN; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MARGINAL ZONE LYMPHOMA; NONHUMAN; PROTEIN DEGRADATION; PROTEINASE INHIBITION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; CASPASE INHIBITORS; CASPASES; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NF-KAPPA B; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 84960425384     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.12.004     Document Type: Review

References (100)

1. Klemm S., et al. The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation. J. Exp. Med. 2006, 203:337-347.
2. Gross O., et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006, 442:651-656.
3. Gringhuis S.I., et al. Selective C-Rel activation via Malt1 controls anti-fungal T(H)-17 immunity by dectin-1 and dectin-2. PLoS Pathog. 2011, 7:e1001259.
4. Ruland J., et al. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003, 19:749-758.
5. Ruefli-Brasse A.A., et al. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 2003, 302:1581-1584.
6. Bornancin F., et al. Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation. J. Immunol. 2015, 194:3723-3734.
7. Gewies A., et al. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation. Cell Rep. 2014, 9:1292-1305. PCT/IB2015/053975, Pub. No.: WO/2015/181747.
8. Yu J.W., et al. MALT1 protease activity is required for innate and adaptive immune responses. PLoS ONE 2015, 10:e0127083.
9. Jaworski M., et al. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. EMBO J. 2014, 33:2765-2781.
10. Thome M. Multifunctional roles for MALT1 in T-cell activation. Nat. Rev. Immunol. 2008, 8:495-500.
11. Ferch U., et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2009, 206:2313-2320.
12. Hailfinger S., et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19946-19951.
13. Fontan L., Melnick A. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma. Clin. Cancer Res. 2013, 19:6662-6668.
14. Nagel D., et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 2012, 22:825-837.
15. Dierlamm J., et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999, 93:3601-3609.
16. Streubel B., et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003, 101:2335-2339.
17. Hu S., et al. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J. Clin. Invest. 2006, 116:174-181.
18. Akagi T., et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999, 18:5785-5794.
19. Morgan J.A., et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res. 1999, 59:6205-6213.
20. Afonina I.S., et al. MALT1 - a universal soldier: multiple strategies to ensure NF-kappaB activation and target gene expression. FEBS J. 2015, 282:3286-3297.
21. Vucic D., Dixit V.M. Masking MALT1: the paracaspase's potential for cancer therapy. J. Exp. Med. 2009, 206:2309-2312.
22. Brustle A., et al. The NF-kappaB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J. Clin. Invest. 2012, 122:4698-4709.
23. Mc Guire C., et al. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination. J. Immunol. 2013, 190:2896-2903.
24. Mc Guire C., et al. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. J. Neuroinflammation 2014, 11:124.
25. Fontan L., et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012, 22:812-824.
26. Cain C. Germinating MALT1. SciBX 2014, 7:133.
27. Pissot Soldermann, C. et al. Novartis AG. Novel pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors, PCT/IB2015/053975.
28. McKinnon M.L., et al. Combined immunodeficiency associated with homozygous MALT1 mutations. J. Allergy Clin. Immunol. 2014, 133:1458-1462.
29. Jabara H.H., et al. A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency. J. Allergy Clin. Immunol. 2013, 132:151-158.
30. Punwani D., et al. Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation. J. Clin. Immunol. 2015, 35:135-146.
31. Hulpiau P., et al. MALT1 is not alone after all: identification of novel paracaspases. Cell. Mol. Life Sci. 2015, Published online September 16, 2015. 10.1007/s00018-015-2041-9.
32. Staal J., et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J. 2011, 30:1742-1752.
33. Hamilton K.S., et al. T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10. Sci. Signal. 2014, 7:ra55.
34. Nakaya M., et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 2014, 40:692-705.
35. Jeltsch K.M., et al. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation. Nat. Immunol. 2014, 15:1079-1089.
36. + helper T cells regulates immune activation. Cell 2013, 153:1036-1049.
37. Ferch U., et al. MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit. Nat. Immunol. 2007, 8:984-991.
38. Tusche M.W., et al. Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J. Exp. Med. 2009, 206:2671-2683.
39. Yang K., Chi H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin. Immunol. 2012, 24:421-428.
40. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 2012, 12:325-338.
41. Gross O., et al. Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production. Blood 2008, 112:2421-2428.
42. Schoenen H., et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. 2010, 184:2756-2760.
43. Zhao X.Q., et al. C-type lectin receptor dectin-3 mediates trehalose 6,6'-dimycolate (TDM)-induced Mincle expression through CARD9/Bcl10/MALT1-dependent nuclear factor (NF)-kappaB activation. J. Biol. Chem. 2014, 289:30052-30062.
44. Hara H., et al. The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat. Immunol. 2007, 8:619-629.
45. Gringhuis S.I., et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat. Immunol. 2012, 13:246-254.
46. McAllister-Lucas L.M., et al. The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J. Biol. Chem. 2010, 285:25880-25884.
47. McAllister-Lucas L.M., et al. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:139-144.
48. Borthakur A., et al. Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. Inflamm. Bowel Dis. 2010, 16:593-603.
49. Delekta P.C., et al. Thrombin-dependent NF-κB activation and monocyte/endothelial adhesion are mediated by the CARMA3.Bcl10.MALT1 signalosome. J. Biol. Chem. 2010, 285:41432-41442.
50. Klemm S., et al. Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:134-138.
51. Mahanivong C., et al. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008, 27:1273-1280.
52. Rehman A.O., Wang C.Y. CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex. Int. J. Oral Sci. 2009, 1:105-118.
53. Martin D., et al. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 2009, 284:6038-6042.
54. Pan D., et al. MALT1 is required for EGFR-induced NF-kappaB activation and contributes to EGFR-driven lung cancer progression. Oncogene 2015, Published online May 18, 2015. 10.1038/onc.2015.146.
55. Pan D., et al. The CBM complex underwrites NF-kappaB activation to promote HER2-associated tumor malignancy. Mol. Cancer Res. 2015, Published online September 21, 2015. 10.1158/1541-7786.MCR-15-0229-T.
56. Uren A.G., et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol. Cell 2000, 6:961-967.
57. Coornaert B., et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat. Immunol. 2008, 9:263-271.
58. Rebeaud F., et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat. Immunol. 2008, 9:272-281.
59. Hailfinger S., et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14596-14601.
60. Rosebeck S., et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011, 331:468-472.
61. Nie Z., et al. Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma. Nat. Commun. 2015, 6:5908.
62. Baens M., et al. MALT1 auto-proteolysis is essential for NF-kappaB-dependent gene transcription in activated lymphocytes. PLoS ONE 2014, 9:e103774.
63. Klein T., et al. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-kappaB signalling. Nat. Commun. 2015, 6:8777.
64. Elton L., et al. MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-kappaB signaling. FEBS J. 2015, Published online November 17 2015. 10.1111/febs.13597.
65. Hachmann J., et al. Mechanism and specificity of the human paracaspase MALT1. Biochem. J. 2012, 443:287-295.
66. Brustle A., et al. MALT1 is an intrinsic regulator of regulatory T cells. Cell Death Differ. 2015, Published online September 25, 2015. 10.1038/cdd.2015.104.
67. Elton L., et al. The multifaceted role of the E3 ubiquitin ligase HOIL-1: beyond linear ubiquitination. Immunol. Rev. 2015, 266:208-221.
68. Ngo V.N., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
69. Davis R.E., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
70. Lenz G., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
71. Compagno M., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
72. Honma K., et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009, 114:2467-2475.
73. Lehmann H.E., Ban T.A. The history of the psychopharmacology of schizophrenia. Can. J. Psychiatry 1997, 42:152-162.
74. Schlauderer F., et al. Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase. Angew. Chem. Int. Ed. Engl. 2013, 52:10384-10387.
75. Lucas P.C., et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J. Biol. Chem. 2001, 276:19012-19019.
76. Suhre K. Inference of gene function based on gene fusion events: the rosetta-stone method. Methods Mol. Biol. 2007, 396:31-41.
77. Copie-Bergman C., et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?. Ann. Oncol. 2005, 16:1232-1236.
78. Nakamura T., et al. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status. Am. J. Gastroenterol. 2008, 103:62-70.
79. Baens M., et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res. 2006, 66:5270-5277.
80. Vicente-Duenas C., et al. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10534-10539.
81. Sawcer S., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
82. Wan Y.Y., et al. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat. Immunol. 2006, 7:851-858.
83. Gerondakis S., et al. NF-kappaB control of T cell development. Nat. Immunol. 2014, 15:15-25.
84. hi T cells bypasses Bcl10: an implication of differential NF-kappaB dependence of naive and memory T cells during T cell receptor-mediated responses. J. Biol. Chem. 2008, 283:24392-24399.
85. Yu O.M., Brown J.H. G protein-coupled receptor and RhoA-stimulated transcriptional responses: links to inflammation, differentiation, and cell proliferation. Mol. Pharmacol. 2015, 88:171-180.
86. Gaide O., et al. CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation. Nat. Immunol. 2002, 3:836-843.
87. Langel F.D., et al. Multiple protein domains mediate interaction between Bcl10 and MALT1. J. Biol. Chem. 2008, 283:32419-32431.
88. Sommer K., et al. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 2005, 23:561-574.
89. Matsumoto R., et al. Phosphorylation of CARMA1 plays a critical role in T cell receptor-mediated NF-kappaB activation. Immunity 2005, 23:575-585.
90. Li S., et al. Structural insights into the assembly of CARMA1 and BCL10. PLoS ONE 2012, 7:e42775.
91. Qiao Q., et al. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Mol. Cell 2013, 51:766-779.
92. Sun L., et al. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 2004, 14:289-301.
93. Wu C.J., Ashwell J.D. NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3023-3028.
94. Oeckinghaus A., et al. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J. 2007, 26:4634-4645.
95. King C.G., et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat. Med. 2006, 12:1088-1092.
96. Misra R.S., et al. Caspase-8 and c-FLIPL associate in lipid rafts with NF-kappaB adaptors during T cell activation. J. Biol. Chem. 2007, 282:19365-19374.
97. Liu S., Chen Z.J. Expanding role of ubiquitination in NF-kappaB signaling. Cell Res. 2011, 21:6-21.
98. Stempin C.C., et al. The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-kappaB activation. J. Biol. Chem. 2011, 286:37147-37157.
99. Dubois S.M., et al. A catalytic-independent role for the LUBAC in NF-kappaB activation upon antigen receptor engagement and in lymphoma cells. Blood 2014, 123:2199-2203.
100. Beyaert R. An E3 ubiquitin ligase-independent role of LUBAC. Blood 2014, 123:2131-2133.